26/03/2026
We had a great time at the Society of Toxicology (SOT) Annual Meeting 2026—thank you to everyone who stopped by, engaged with our team, comprising Jomy Jose and Sonela Cavicke, and showed interest in our work.
It was encouraging to see strong participation around our poster presentations, with many insightful discussions on how early safety assessment can shape better outcomes in drug discovery.
At Sai Life Sciences, one of the things we focus on is helping drug discovery teams identify safety risks early—before they become late-stage setbacks. At SOT this year, we shared two pieces of work that reflect this approach:
▪️ Poster 5187 | Bringing bioenergetics to the forefront
Our journey in validating Seahorse-based mitotoxicity goes beyond assay development—it’s about giving scientists an earlier, clearer window into mitochondrial risk.
▪️ Poster 5227 | Modality-specific hepatotoxicity assessment
Small molecules and ASOs don’t behave the same—so why assess them the same way? Our spheroid + liver-on-chip NAM toolbox demonstrates how modality-tailored models sharpen prediction and reduce uncertainty.
If you missed connecting with us at the event, feel free to write to contact@sailife.com. We look forward to building on these discussions.
